Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

By simulating various scenarios, predictive models help public health officials weigh the trade-offs between different ...

Now is the time for policy makers, payers, health systems, and clinicians to act decisively by extending AHCaH, evaluating ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

The Guiding an Improved Dementia Experience (GUIDE) model could be further strengthened by enhancements and clarifications of ...

Health Affairs' Jeff Byers welcomes Farzad Mostashari, founder & CEO of Aledade and the former National Coordinator for ...